The advancement of nanobiotechnology has led to the development of various techniques for addressing target-specific drug delivery issues. In this article, we successfully developed a supramolecular self-assembly approach for the fabrication of polyacrylate-based nanoparticles with simultaneous loading of the anticancer drug doxorubicin (DOX) for targeted delivery towards cancer treatment in vitro and in vivo. Two types of polyacrylates functionalized with adamantane and β-cyclodextrin respectively could self-assemble to form supramolecular nanoparticles through strong host–guest complexation between adamantane and β-cyclodextrin. Folic acid was incorporated within the supramolecular nanoparticles in order to impart the targeting specificity towards selected cancerous cell lines, namely MDA-MB231 and B16-F10. The as-synthesized supramolecular nanoparticles were fully characterized by several techniques, revealing an average nanoparticle size of 35 nm in diameter, which is small enough for excellent blood circulation. The cytotoxicity studies indicate that the supramolecular nanoparticles without drug loading were non-cytotoxic under the concentrations measured, while DOX-loaded supramolecular nanoparticles showed significant cytotoxicity. In order to investigate the targeting specificity of DOX-loaded supramolecular nanoparticles towards the cancerous cells, a healthy cell line model HEK293 was employed for carrying out the comparison studies. Due to the presence of the targeting ligand, experimental results demonstrate that the supramolecular nanoparticles were highly specific for targeting the cancerous cells, but not for HEK293 cells. After the in vitro investigations, the in vivo drug delivery study using DOX-loaded supramolecular nanoparticles was performed. Tumor-bearing nude mice were treated with DOX-loaded supramolecular nanoparticles, and the analysis results indicate that DOX-loaded supramolecular nanoparticles have the capability to enhance the therapeutic effects of DOX for effectively inhibiting the tumor growth. Thus, the self-assembled polymeric nanoparticles exhibit a highly promising potential to serve as drug carriers for targeted drug delivery towards improved cancer treatment.
纳米
生物技术的进步导致了解决特定目标药物输送问题的各种技术的发展。在本文中,我们成功开发了一种超分子自组装方法,用于制造基于聚
丙烯酸酯的纳米颗粒,同时负载抗癌药物
阿霉素(DOX),用于体外和体内癌症治疗的靶向递送。两种分别用
金刚烷和β-
环糊精功能化的聚
丙烯酸酯可以通过
金刚烷和β-
环糊精之间的强主客体络合自组装形成超分子纳米粒子。将叶酸掺入超分子纳米颗粒中,以赋予针对选定癌
细胞系(即
MDA-MB231 和 B16-F10)的靶向特异性。通过多种技术对合成的超分子纳米颗粒进行了全面表征,显示平均纳米颗粒尺寸为直径 35 nm,足够小,可以实现良好的血液循环。细胞毒性研究表明,未负载药物的超分子纳米颗粒在测量浓度下无细胞毒性,而负载DOX的超分子纳米颗粒则表现出显着的细胞毒性。为了研究负载DOX的超分子纳米粒子对癌细胞的靶向特异性,采用健康
细胞系模型HEK293进行比较研究。由于靶向
配体的存在,实验结果表明超分子纳米颗粒对于靶向癌细胞具有高度特异性,但对于 HEK293 细胞则不然。在体外研究之后,进行了使用负载DOX的超分子纳米颗粒的体内药物递送研究。用负载DOX的超分子纳米颗粒治疗荷瘤裸鼠,分析结果表明负载DOX的超分子纳米颗粒能够增强DOX的治疗效果,有效抑制肿瘤生长。因此,自组装聚合物纳米颗粒表现出作为药物载体用于靶向药物递送以改善癌症治疗的非常有前途的潜力。